» Articles » PMID: 32869188

Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors

Overview
Journal Endocr Pathol
Specialties Endocrinology
Pathology
Date 2020 Sep 2
PMID 32869188
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Gastrointestinal tract neuroendocrine neoplasms (NENs) are a group of rare heterogeneous tumors with different prognoses. The 2019 WHO classification of digestive system tumors defines the classification of NENs as neuroendocrine tumors (NETs G1-G3) and neuroendocrine carcinomas (NECs). We investigated outer dense fiber of sperm tails 1 (ODF1) expression in 137 gastrointestinal tract NENs including 53 NETs G1, 29 NETs G2, 3 NETs G3, and 52 NECs. Twenty adenocarcinomas and 6 squamous cell carcinomas also were included in the study. The results showed that ODF1 was positive in 83 of 85 (97.6%) primary gastrointestinal tract NETs, including 9 of 10 (90%) gastric, 19 of 19 (100%) small bowel, 10 of 11 (90.9%) colorectal, and 45 of 45 (100%) appendiceal neoplasms. There was a significantly statistical difference in the rates of ODF1 positivity in NETs (83/85, 97.6%) vs NECs (25/52, 48.1%, P < 0.001). ODF1 showed diffuse staining in NETs G1 (53/53, 100%) and NETs G2 (28/29, 96.6%), > 50% staining in NETs G3 (2/3, 66.7%), and focal staining (< 50%) in NECs (23/52, 44.2%) but 2 cases (2/52) showed > 50% staining. ODF1 showed no expression in all 20 adenocarcinomas and 6 squamous cell carcinomas. In conclusion, ODF1 was firstly identified as a novel marker for NENs, especially for NETs in the gastrointestinal tract. The expression mechanism and clinical significance of ODF1 in NENs needed further study.

Citing Articles

Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer.

Shi R, Zhou X, Pang L, Wang M, Li Y, Chen C Cancer Immunol Immunother. 2022; 72(4):985-1001.

PMID: 36251028 PMC: 10991242. DOI: 10.1007/s00262-022-03307-0.


Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.

Mete O, Wenig B Head Neck Pathol. 2022; 16(1):123-142.

PMID: 35312985 PMC: 9018952. DOI: 10.1007/s12105-022-01435-8.


Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens L Endocr Pathol. 2022; 33(1):115-154.

PMID: 35294740 DOI: 10.1007/s12022-022-09708-2.


Insights on Human Small Heat Shock Proteins and Their Alterations in Diseases.

Tedesco B, Cristofani R, Ferrari V, Cozzi M, Rusmini P, Casarotto E Front Mol Biosci. 2022; 9:842149.

PMID: 35281256 PMC: 8913478. DOI: 10.3389/fmolb.2022.842149.

References
1.
Sorbye H, Baudin E, Perren A . The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Endocrinol Metab Clin North Am. 2018; 47(3):683-698. DOI: 10.1016/j.ecl.2018.05.001. View

2.
Kim H, Lee H, Nam K, Choi J, Kim W . Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2015; 35(6):3501-10. View

3.
Jiao Y, Shi C, Edil B, de Wilde R, Klimstra D, Maitra A . DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331(6021):1199-203. PMC: 3144496. DOI: 10.1126/science.1200609. View

4.
Park J, Paik W, Lee K, Ryu J, Lee S, Kim Y . DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget. 2017; 8(30):49796-49806. PMC: 5564808. DOI: 10.18632/oncotarget.17964. View

5.
Tang L, Basturk O, Sue J, Klimstra D . A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016; 40(9):1192-202. PMC: 4988129. DOI: 10.1097/PAS.0000000000000662. View